Update: Missouri judge approves Bayer's $7.25 billion Roundup deal, paid over up to 21 years
The ruling comes after the November 3 timing we reported. Average payouts run from $10,000 to $165,000, and the order says $3 billion is due in the first five years.
A St. Louis judge on Friday gave final approval to Bayer's $7.25 billion nationwide settlement of Roundup cancer claims, according to the Associated Press and Agri-Pulse. On Nov. 3 Bayer's CEO said it could come "any week now". This is that decision, and it can still be appealed.
What the order says
Circuit Judge Timothy Boyer called the average payouts "fair and adequate," found no evidence of collusion, and said the 18 months of negotiation were "extensive, hard-fought and at arm's length," per Agri-Pulse. The deal covers two groups: people exposed before Feb. 17, 2026 who have a non-Hodgkin lymphoma diagnosis now, and people diagnosed within 16 years of final approval. AP reports Bayer pays into a fund annually for up to 21 years, and that average awards range from $10,000 to $165,000 depending on use, age at diagnosis and severity.
The number behind the number
Spread evenly over 21 years, $7.25 billion is about $345 million a year (7,250 / 21). But the judge's order says current claimants' counsel won $3 billion of funding in the first five years. If that sits inside the $7.25 billion, as the order's wording suggests, early payments average about $600 million a year (3,000 / 5), and the remaining $4.25 billion stretches over the later years. We have not seen the payment schedule itself, so treat that as our arithmetic, not a Bayer figure.
It is also on top of money already set aside: AP says Bayer previously reserved $16 billion for Roundup legal costs. The order cites over 30,000 cases in Missouri courts alone, against just over 200 plaintiffs with trial dates, which is the court's case for settling rather than trying them one by one.
Why the Supreme Court ruling matters here
The judge leaned on the 7-2 Durnell decision in June, which held that federal law blocks state failure-to-warn claims, the "principal legal theory" of the litigation. Bayer calls the settlement and that ruling "mutually reinforcing pillars." Plaintiffs' lawyers are split: court-appointed counsel Christopher Seeger says it delivers guaranteed compensation, while attorney Gerson Smoger argued in September that it locks in future claimants for decades.
Who it touches
For investors, a cap on a long-running liability is the headline. Bayer's ADR (BAYRY) closed at $15.02 before the ruling, so the market has not yet reacted. For farmers, the product is not pulled: AP says the company has changed only its residential formula, and Smoger notes the product stays on the market. For landscapers, lawn-care crews and farm workers who have applied glyphosate for years, AP says agricultural, industrial and turf workers exposed at length sit in the higher payout tiers. Whether anyone qualifies depends on the class notice and a diagnosis. Anyone who thinks they might should read that notice or ask a lawyer.
Sources: AP via PBS News; Agri-Pulse; share price from Yahoo Finance. This is market information, not investment advice or legal advice.
Want your business to be the answer?
Get a full package of articles about your business, built so customers, Google and AI assistants can find you.
New ebook from The Company ChronicleHow to Research Like a Wall Street AnalystFind original sources, analyze trends, and build your own insights. 36 pages with worksheets.Get the ebook · $29Instant PDF download

